New "Monsterpocalypse" releases: Ulgoth, Apes, and Robots, Oh My! – Bleeding Cool News

Monsterpocalypse from Privateer Press is unlike any other miniature game on the market. Players assemble and paint teams of giant monsters, then bring those monsters together to fight it out over a model city. Monsterpocalypse takes everything you love about Godzilla, King Kong, Ultraman, and Power Rangers and puts it all into the palm of your hand.

The latest Monsterpocalypse releases had a lot to offer just about anyone who loves giant monsters! Im going to start with the latest Kingdom of the Apes releases, since, well, giant fighting apes.

Thought to have emerged from somewhere within the harshest and most inaccessible peaks of the Himalayas, White Dajan is a ferocious giant ape that has emerged to confront Earths would-be despoilers. Possessing the power to summon winters ferocity, White Dajan is noted for his rage and unbridled violence even among the Empire of the Apes. He seems to have a particular hatred for buildings and crowded cities, seeking to level such structures whenever his anger is provoked. This makes him a perilous guardian, though he has also shown affection for humanity and a willingness to fight alongside them. Considering the foes Earth faces, a few toppled buildings are considered an acceptable price to pay to appease this formidable ally.

White Dajan also gets a little reinforcement from these crazy ape bombers, who appear to be riding bombs into battle!

Though the most gargantuan of the great apes might be mistaken for unthinking beasts, their intelligence is demonstrated by their ground forces, who possess borrowed technology that they utilize with uncanny sophistication. Ape bombers soar through the air on jury-rigged portable jet engines, capable of dropping high-yield explosives with considerable accuracy. And command apes have been witnessed making use of radio communication devices to orchestrate attacks, despite the fact that the language they employ seems like nothing but gibberish to human ears.

The Lords of Cthul have a new beastie, a nasty looking monster called Ulgoth:

An otherworldly embodiment of toxicity and pain, Ulgoths very blood destroys what he does not directly assault, and the world itself shudders in his passage. Unlike some other Lords of Cthul, it is difficult to determine if Ulgoth is even intelligent, so far as humanity is concerned, as it seems almost more a force of supernatural destruction and transformation. Wherever it treads, the world is changed around it, and some scientists have theorized Ulgoth might be akin to a sinister terraforming device, one bent on changing the very nature of the Earth into an environment more amenable to creatures of Cthul. It is also responsible for hastening the proliferation of lesser horrors from their reality, spawning and summoning such beings with a frequency that defies reason.

Ulgoth is not the type of monster that will be shown up by some damned dirty ape, so it brought its own reinforcements into battle:

It is difficult for even the brightest minds of humanity to understand the fiendish creatures of the Lords of Cthul. Snatchers are among the most feared of their lesser minions, bloated hovering creatures capable of seizing hapless victims and transforming them into a similar biomass of Cthulians. Against such a fate, some might consider the alternative of being torn apart by a swooping Hellion to be preferable. Hellions are batlike hunters capable of swift movement and similarly swift foe neutralization.

Finally, for those of you who like your giant, stomping Monsterpocalypse action in a mechanized form, there is Gorghadratron, who fights for whoever can afford its massive price tag:

Nothing demonstrates the military manufacturing capabilities of UberCorp International better than its gigantic weaponized hardware platforms, each customized to monstrous configurations. Gorghadratron brings the raw obliterating power of the so-called Planet Eaters to anyone with sufficient funds to commit to an exclusive purchasers license. Built with innovative polymers and alloys derived from recovered xenoexobiological materials, Gorghadratron is as durable as it is lethal, with longevity assured by the recommended 10-year UberCorp maintenance contract, purchased separately. UberCorp cannot be held responsible for any collateral damage incurred by overloading Gorghadratrons reactors.

Leigh George Kade is a writer, illustrator, and sculptor who lives in Salt Lake City with his wife and two small Skrulls. Leigh has also been a panelist on the wildly popular Geek Show Podcast since 2008. He has been an Entertainment Writer for Bleeding Cool since 2018.

Go here to read the rest:

New "Monsterpocalypse" releases: Ulgoth, Apes, and Robots, Oh My! - Bleeding Cool News

Space Shipment Launched With Sports Car Parts, Cookie Oven – The New York Times

A supply ship rocketed toward the International Space Station on Saturday with sports car parts, an oven for baking cookies and a vest to protect against radiation.

Northrop Grumman launched its Cygnus capsule for NASA from Wallops Island, Virginia. The 8,200-pound shipment (3,700 kilograms) should reach the orbiting lab Monday.

"Good launch all the way around," a ground controller observed.

The space station's astronauts will test the oven by baking chocolate chip cookies and try out the new safety vest to gauge its comfort. Both experiments are seen as precursors to moon and Mars journeys.

Other newly arriving equipment will be used in a series of NASA spacewalks later this month to fix a key particle physics detector. Parked outside the space station since 2011, the Alpha Magnetic Spectrometer needs new cooling pumps to continue its search for elusive dark matter and antimatter.

Italy's Lamborghini is also along for the ride. It's sending up samples of carbon fiber used in its sports cars for six months of direct space exposure. Researchers are considering the materials for medical implants.

Like space, the insides of a person's body are an extreme environment, explained Houston Methodist's Alessandro Grattoni, who is collaborating with Lamborghini on the experiment. As a nanomedicine specialist, he said Friday he's continuously on the lookout for new materials for devices that are inserted beneath the skin. These minuscule implants release therapeutic drugs to treat cancer, hormone deficiencies and other illnesses.

Northrop Grumman is now controlling two Cygnus capsules in orbit, a first for the Virginia-based company. Named for the swan constellation, the Cygnus launched last spring is flying free of the 250-mile-high (400-kilometer-high) space station, after completing its grocery run. It will be directed to a fiery re-entry sometime in the near future, taking station trash down with it, according to company officials.

The newest Cygnus is officially called the S.S. Alan Bean after the Apollo 12 astronaut who became the fourth man to walk on the moon 50 years ago this month. He later commanded NASA's first space station, Skylab, and became known for his cosmic-themed paintings. He died last year.

NASA has contracted with Northrop Grumman and SpaceX to keep the space station stocked. This is Northrop Grumman's 12th successful Cygnus flight since 2013. The company has upgraded both its Cygnus and Antares rocket to haul more cargo from NASA's Wallops Flight Facility on the eastern Virginia shore.

The space station is currently home to three Americans, two Russians and one Italian.

Continue reading here:
Space Shipment Launched With Sports Car Parts, Cookie Oven - The New York Times

Global Egg Phosphatidylcholine Industry: Sales, Revenue, Market Share and Competition by Manufacturer Covered in a Latest Research – Market Research…

Egg Phosphatidylcholine appear to regulate cholesterol absorption and inflammation.

Access Report Details at: https://www.themarketreports.com/report/global-egg-phosphatidylcholine-market-by-manufacturers-regions-type-and-application-forecast

Market share of global Egg Phosphatidylcholine industry is dominate by companies like Nutrasal, Avanti Polar Lipids, Lipoid, Natural Factors, Kewpie, NOF, Jena Bioscience, Vitamin Research Products and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018).

With the help of 15 chapters spread over 100 pages this report describe Egg Phosphatidylcholine Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Egg Phosphatidylcholine, in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2019 to 2024 is provided in this research report. At last information about Egg Phosphatidylcholine sales channel, distributors, traders, dealers, and research findings completes the global Egg Phosphatidylcholine market research report.

Market Segment by Regions, regional analysis covers:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia, etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

Choline

Serine

Inositol

Ethanolamine

Market Segment by Applications, can be divided into

Cosmetics

Pharmaceutical

Dietary Supplements

Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1491809

Table of Contents

1 Market Overview

2 Manufacturers Profiles

3 Global Egg Phosphatidylcholine Market Competitions, by Manufacturer

4 Global Egg Phosphatidylcholine Market Analysis by Regions

5 North America Egg Phosphatidylcholine by Countries

6 Europe Egg Phosphatidylcholine by Countries

7 Asia-Pacific Egg Phosphatidylcholine by Countries

8 South America Egg Phosphatidylcholine by Countries

9 Middle East and Africa Egg Phosphatidylcholine by Countries

10 Global Egg Phosphatidylcholine Market Segment by Type

11 Global Egg Phosphatidylcholine Market Segment by Application

12 Egg Phosphatidylcholine Market Forecast (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1491809

Read the rest here:
Global Egg Phosphatidylcholine Industry: Sales, Revenue, Market Share and Competition by Manufacturer Covered in a Latest Research - Market Research...

Global Healthcare Nanotechnology (Nanomedicine) Industry Research: Key Companies Profile with Sales, Revenue, Market Share, Price and Competitive…

With the help of 15 chapters spread over 100 pages this report describe Healthcare Nanotechnology (Nanomedicine) Introduction, product scope, market overview, market opportunities, market risk, and market driving force. Later it provide top manufacturers sales, revenue, and price of Healthcare Nanotechnology (Nanomedicine), in 2017 and 2018 followed by regional and country wise analysis of sales, revenue and market share. Added to above, the important forecasting information by regions, type and application, with sales and revenue from 2018 to 2024 is provided in this research report. At last information about Healthcare Nanotechnology (Nanomedicine) sales channel, distributors, traders, dealers, and research findings completes the global Healthcare Nanotechnology (Nanomedicine) market research report.

Access Report Details at:https://www.themarketreports.com/report/global-healthcare-nanotechnology-nanomedicine-market-by-manufacturers-countries-type-and-application-forecast

Market share of global Healthcare Nanotechnology (Nanomedicine) industry is dominate by companies like Abbott Laboratories, Combimatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Mallinckrodt Plc, Merck & Company Inc., Nanosphere Inc., Pfizer, Inc., Celgene Corporation and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2018-2019).

Market Segment by Regions, regional analysis covers:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia, etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

Biochip

Implant Materials

Medical Textiles

Wound Dressing

Other

Market Segment by Applications, can be divided into

Therapeutic

Diagnostic

Research

Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/1503245

Table of Contents

1 Market Overview

2 Manufacturers Profiles

3 Global Healthcare Nanotechnology (Nanomedicine) Market Competitions, by Manufacturer

4 Global Healthcare Nanotechnology (Nanomedicine) Market Analysis by Regions

5 North America Healthcare Nanotechnology (Nanomedicine) by Countries

6 Europe Healthcare Nanotechnology (Nanomedicine) by Countries

7 Asia-Pacific Healthcare Nanotechnology (Nanomedicine) by Countries

8 South America Healthcare Nanotechnology (Nanomedicine) by Countries

9 Middle East and Africa Healthcare Nanotechnology (Nanomedicine) by Countries

10 Global Healthcare Nanotechnology (Nanomedicine) Market Segment by Type

11 Global Healthcare Nanotechnology (Nanomedicine) Market Segment by Application

12 Healthcare Nanotechnology (Nanomedicine) Market Forecast (2019-2024)

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

Ask your report related queries at: https://www.themarketreports.com/report/ask-your-query/1503245

Link:
Global Healthcare Nanotechnology (Nanomedicine) Industry Research: Key Companies Profile with Sales, Revenue, Market Share, Price and Competitive...

Nanomedicine Market Analysis by Growth, Segmentation, Performance, Competitive Strategies with Top Players Pfizer Inc., CELGENE CORPORATION, Teva…

Nanomedicine Market report has been structured after a thorough study of various key market segments like market size, latest trends, market threats and key drivers which drives the market. This market study report has been prepared with the use of in-depth qualitative analysis of the global market. The report displays a fresh market research study that explores several significant facets related to Nanomedicine Market covering industry environment, segmentation analysis, and competitive landscape. This global market research report is a proven source to gain valuable market insights and take better decisions about the important business strategies.

Industry Analysis:

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Top Dominating Competitors are: Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Nanomedicine Market Report incorporates the precisely contemplated and surveyed information related to the Nanomedicine Market by utilizing various explanatory tools and techniques. The explanatory devices, for example, PEST analysis, Porters five Forces examination, SWOT investigation, speculation return examination and feasibility analysis have been utilized to break down complex Nanomedicine Market data.

Market Drivers and Restraint:

Table of Contents:

Chapter 1 Industry Overview:

Chapter 2 Premium Insights

Chapter 3 Production Market Analysis:

Chapter 4 Major Market Classification:

Chapter 5 Major Application Analysis:

Chapter 6 Industry Chain Analysis:

Chapter 7 Major Manufacturers Analysis:

Chapter 8 New Project Investment Feasibility Analysis:

Chapter 9 Market Driving Factors:

Explore Full Report with Detailed TOC Here at https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Geographical landscape

Have look on the Premium Insights of the Report

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Original post:
Nanomedicine Market Analysis by Growth, Segmentation, Performance, Competitive Strategies with Top Players Pfizer Inc., CELGENE CORPORATION, Teva...

Nanovehicles that mimic nature could deliver treatments of the future – ScienceBlog.com

But Prof. Cauda and her colleagues on theTrojaNanoHorse projecthave developed a shell around the crystals so they can slip them past the bodys defences and inside cancer cells.

The idea is to elude the immune system and to elude the barrier of the cell membrane thanks to the biomimetic shell, says Prof. Cauda. In the Trojan horse analogy, the (cancer) cell can be the city of Troy.

Fatty

The tiny shells, which are between 100-200nm or 1,000 times smaller than a human hair, are made from fatty molecules called lipids that form the outer membrane of almost all living cells. In nature, small droplets made from these lipids known as vesicles constantly bud off from the surface of our cells with chemical messages or unwanted materials inside so they can be carried safely to other parts of the body.

Prof. Cauda and her team have tried to copy this by coating their nanocrystals in vesicles produced by cells grown in the lab so they too can pass harmlessly through the body. The surface of the vesicles can also be studded with antibodies against specific cancer cells, helping them to hone in on only the cells they want to kill.

Once a vesicle finds a cancer cell, its antibodies will bind to the surface, allowing the lipids to merge with the cell and releasing the toxic nanocrystal inside. And by growing nanoshells from cells taken from a patients own body, Prof. Cauda believes it will be possible to create personalised treatments that can evade the immune system while still killing cancer cells.

The team have already tested the nanoshell approach against leukaemia cells and cervical cancer in the laboratory. While they hope to be able to perform human trials in the future, Prof. Cauda warned it could still be many years before they reach that stage.

Benefits

If successful, however, this nanomedicine approach could bring benefits compared to traditional chemotherapy treatments by only targeting tumour cells, leaving healthy tissue unaffected and so reducing side-effects.

The nanomedicine approach could offer a site-selective and personalised treatment for the patient, said Prof. Cauda.

In the Trojan horse analogy, the (cancer) cell can be the city of Troy.

Professor Valentina Cauda, Politecnico di Torino, Italy

This approach, however, still largely relies upon the nanoshells chancing upon the cancer cells as they circulate in the patients bloodstream so they can attach to them.

Another team of researchers are working on nano- and micro-machines that might actively be able to improve this by carrying treatments to the site in the body where they are needed.

Dr Larisa Florea, a materials scientist at Trinity College Dublin in Ireland, is leading a project calledChemLifeto create miniature vehicles that can move by themselves in a liquid.

Chemotaxis

The team is attempting to emulate a form of movement known as chemotaxis, which is employed by some basic microorganisms and enables them to move through solutions from low salinity to high salinity, or from acidic to alkaline solutions, for example.

Other research teams in the US have previously shown that man-made droplets can be very preciselynavigated through complex mazeswith this approach. Dr Florea and her colleagues have sought to extend this by using light to control the movement of droplets.

They have created vesicle-like droplets that pair light sensitive molecules with compounds known as surfactants. Surfactants are commonly found in detergents but are also commonly found in many biological systems.

When exposed to light, the photosensitive molecules react by changing their shape, altering the surface tension on each side of the droplet. This causes the molecules in the droplet to flow from one side to the other, driving it forward, a little like the tread of a tank.

The team have shown they can accurately steer dropletsthrough three dimensional spacesandreach speeds of up to 10.4mm per second(0.02mph).

By adding a photoactive material to a droplet, scientists have been able to control its movement in three dimensions through water using light.

If you compare the speed of the movement to the size of these microdroplets, they are faster, pound for pound, than some of the best swimmers in the world, said Dr Florea.

They have also been able to demonstrate that their droplet-shaped vehicles can carry cargo, delivering it to other droplets to trigger a chemical reaction. It raises hopes that similar methods could be used to deliver drugs or other sorts of treatments to specific cells in the body.

While it may be difficult to use light to navigate a drug-carrying droplet through the body, Dr Florea and her colleagues have also explored using mild electrical currents.

Propel

The team have also been developing more complex micromachines that can swim or crawl through liquids like tiny bacteria. Using highly precise 3D printing techniques, they have beenable to create hydrogel structuresaround a few micrometres in size that can contract and expand to propel a structure forward.

We have been making tiny flower-like structures, for example, that can open and close in response to different stimuli, she said. For example it might open at a certain pH and close at another.

This happens because the hydrogels expand by absorbing water and contract by expelling it according to the pH of the surrounding solution.Dr Florea said they hope to also control the movement of hydrogels with changes in temperature or pulses of light.

The ChemLife team are using these hydrogels to create structures with tiny rotating flagella the tiny tail-like appendages that some bacteria use to propel themselves. They are also creating worm-like structures from the same kind of hydrogels that can crawl along surfaces or through liquids.

The ultimate goal is to have these micro-vehicles perform actions like drug delivery or (chemical) sensing, said Dr Florea. But we have to be realistic that this might not be achieved in the near future as the body is a very difficult environment.

The tiny moving structures could also find uses in other ways too. These include delivering chemicals to better improve industrial reactions or creating soft micro-grippers that could be remotely activated to handle delicate components like cells without damaging them.

When you look at what nature can achieve, the opportunities are endless, added Dr Florea.

The research in this article was funded by the EUs European Research Council. If you liked this article, please consider sharing it on social media.

Originally published on Horizon.

More:
Nanovehicles that mimic nature could deliver treatments of the future - ScienceBlog.com

The benefits of intermittent fasting – Starjournalnow

By Wendy M. HenrichsBoard Certified Chiropractic Pediatrician and Nutrition Counselor

Is your diet in need of a reboot before the holidays? Remember that your diet is how and what you eat, not something that you do for a short period of time to lose weight. There are several popular diet patterns today, including Keto, Paleo, Gluten Free, Low Carb, High Protein, Whole 30, and Mediterranean. The number one diet pattern in 2018 was Intermittent Fasting. This article will explore intermittent fasting and its benefits. If you are looking for ways to manage your weight, decrease inflammation and pain, lower your blood pressure, lower your total cholesterol, decrease your risk for heart disease and diabetes along with having more energy and longevity then intermittent fasting could be for you.

Fasting originated in ancient evolution and healing tradition across millennia. It has been shown to support overall metabolic health. It supports cellular cleanup which leads to cellular regeneration and an increase in circulating stem cells (i.e. younger cells). It impacts genetic markers associated with an increase in human longevity and health span.

Fasting is not a fad. In Obesity 2019, those practicing time-restricted eating within a six-hour period and fasting for 18 hours improved fat-burning and lowered levels of the hungry hormone ghrelin, as compared to those who ate exact same meals in 12-hour period. Eating only during limited hours can improve weight management, increase longevity, and improve our immune systems ability to fight disease. Mt. Sinai researchers published a study (Cell, Aug. 22, 2019) showing that fasting reduces inflammation and improves chronic inflammatory diseases without affecting the immune systems response to acute infections. Intermittent fasting is known to improve sensitivity to blood glucose, lower blood glucose, protect against fatty liver, and lower pancreatic fat.

There are several approaches to intermittent fasting but, in my opinion, a 12-16 hour fasting period that includes breakfast and eating your last meal before 6 p.m. is doable for the average person with a multitude of benefits. A study published in Nutrients 2019 compared the effects of eating a high fat, high sugar diet (the Standard American Diet-SAD) to a 12-16-hour intermittent fasting diet. Eating more than six meals and snacks daily while skipping breakfast, eating high fat and high sugar, and eating the last meal later at night with a reduced fasting period causes increased hunger, inflammation and total cholesterol, and a decrease in insulin sensitivity. Just skipping breakfast leads to increased LDLs, increased body fat, increased weight and an increased incidence of diabetes. Eating breakfast and eating your last meal before 6pm with a fasting period between 12-16 hours has many positive effects such as decreased hunger, decreased inflammation (leads to decreased pain), decreased total cholesterol and increased insulin sensitivity. There were also decreases in LDLs, blood pressure, body weight, body fat and a decreased risk of diabetes and heart disease. These are some very compelling reasons to consider intermittent fasting.

Some things to keep in mind if you are considering intermittent fasting: Eat Breakfast: Breakfast is the most important meal of the day. It ignites your metabolism and your brain. Breakfast should include protein, healthy fats (avocado, grass-fed organic butter, salmon, omega 3 eggs, nuts or seeds), fruit or vegetables. Skipping breakfast leads to increases in body weight, body fat, LDLs and risk of diabetes. Eat Dinner/Supper before 6 p.m. (if possible): Eating later at night leads to increases in fat deposition, blood pressure, cholesterol and increased risk of diabetes and heart disease. I suggest brushing your teeth after supper which helps prevent the evening noshing. Your dinner should include four ounces of lean protein (organic chicken, grass fed beef, wild game, wild caught fish, or legumes) paired with one to two cups of steamed vegetables and/or leafy greens. If you must have starch, limit it to a half-cup serving. Eat three meals a day with two small snacks (if needed) that include protein, good fats, veggies and/or fruits. Fast for 12-16 hours between supper and breakfast: This improves your ability to burn stored fat, which amps up your metabolism. Eat whole foods that do not come from boxes or packages. That is, eat mostly plant derived food like fresh or frozen fruits and vegetables plus lean protein sources such as eggs, organic chicken, grass fed beef, wild game, wild caught fish, legumes and nuts. Eat organic foods as much as possible. Visit http://www.ewg.org for the dirty dozen and clean 15 as a guide. Eat good fats from grass fed butter, olive oil, coconut oil, avocado oil and grape seed oil. Drink half of your body weight in ounces of water daily. Try for eight ounces of water per hour throughout your waking hours. Avoid trans fats, hydrogenated and partially hydrogenated oils/fats.

Intermittent fasting was used by our ancestors, sometimes out of necessity. It is a way to lower your blood pressure, lower your cholesterol and LDLs, decrease your risk for diabetes and heart disease along with long term weight management while increasing energy and longevity. Consider intermittent fasting as a means to not only live longer but get more life out of your years.

Dr. Wendy Henrichs is a board certified chiropractor and nutrition counselor at Timber Land Chiropractic in Rhinelander. For a complimentary chiropractic, nutrition or lifestyle counseling consultation, visit TimberlandChiropractic.com, Facebook, or call 715-362-4852.

See the original post:

The benefits of intermittent fasting - Starjournalnow

What bamboo forests do for nature and human well-being – Forests News, Center for International Forestry Research

Kiran Paudyal is an ecosystems services specialist at Forest Action Nepal. Chun Bahadur Gurung, is a development communication specialist and Ph.D. candidate at Tribhuvan University in Nepal.

Bamboo, which belongs to the grass family, is one of the fastest growing species of the plant kingdom. Its herculean attributes are not at first obvious when encountered in the forest. Although its hollow stems that bend in the wind may make it appear weak, its provision of a wide variety of ecosystem services defined as the direct and indirect contributions of ecosystems to human well-being, makes this an invaluable plant.

Found in tropical and alpine climatic zones of Africa, Asia, Central and South America, scientists have so far recorded more than 1,600 bamboo species, which combined cover more than 31 million hectares of land.

With myriad potential uses, bamboo is an essential material for people living in poverty in developing countries. It is widely used as a raw material in industry, in handicrafts, its fibers are used to weave clothes and make paper, and its shoots and sprouts are used for food.

It may be no surprise then, that bamboo features heavily in cultural traditions. In Indonesia, it is used in ceremonies and in the construction of such instruments as the Balinese rindik. In China, its symbolism of modest character and longevity is heralded; in rural Nepal, babies sleep in beautiful bamboo cradles and the dead are buried in bamboo coffins.

From floods to good fortune in Nepal

Nepal a landlocked country is blessed with bamboo diversity. The country has more than 53 species covering an estimated area of 63,000 hectares of land.

Nepal has a tale to tell, a story of 70 households from Gauringar village, Chitwan, in the center of the country. In 2010, incessant rain caused flash floods. Homes and buildings near the Rui river in Gauringar were destroyed. When the river banks were washed away, tons of silt and sand flooded the land, rendering it infertile.

The resilient residents worked hard to reverse their fortunes: in their efforts, they planted 10,000 native bamboo seedlings. In less than a decade, the flood-ravaged land turned into a beautiful bamboo forest. Some 700 hectares of land were rehabilitated, allowing local communities to enjoy bamboo shoots for food and all of the benefits the bamboo forest provides. The new forest has even become instrumental in mitigating human-wildlife conflict, as Gauringar sits in the buffer zone of Chitwan National Park, home to the rhino, sloth bear, tiger, elephant, wild boar and leopard.

Bamboo for water and energy in Indonesia

Across the Indonesian archipelago, bamboo can be found in 30 provinces, covering 2.1 million hectares of land. By selling bamboo shoots, a farmer on Java can earn $420700 per hectare, while others have recognized it for its incredible restoration properties. Scientist Yusuf Samsudin at the Center for International Forestry Research (CIFOR) reports how payments for environmental services (PES) have been awarded to communities living up-stream of Mount Batur and its lake in Bali, where the main water source for coastal communities flows. While many trees store around 35 to 40 percent of rainfall, bamboo can store up to 90 percent of rainfall.

Bamboo can provide sustainable supplies of biomass for energy productionwithout compromising food security or unduly affecting the wider landscape. One of CIFORs partners Clean Power Indonesia successfully developed a community-based power plant that uses biomass from bamboo in rural Indonesia. CIFOR Senior Scientist Himlal Baral says that CIFOR and partners are currently looking for opportunities to scale this up in several locations in Indonesia.

Untapped green good in Ethiopia

In Ethiopia, two main bamboo species (Arundinaria alpine and Oxytenanthera abyssinica) grow naturally in six regions on a million hectares of land, making up 8.2 percent of the total forest area of the country.

However, bamboo was close to extinction in natural forests due to agriculture-related deforestation and forest degradation, and demand for fuelwood and timber in the villages. In the 1990s, more than 100 innovative smallholders planted savanna bamboo within agroforestry systems using a rhizome offset method from the natural forest, developing bamboo forests in the villages for multiple benefits.

Although bamboo coverage has been high in Ethiopia in recent years, uses have been traditional, and its full export market potential has yet to be realized.

Because bamboo is a fast-growing species and adapts to harsh environments, people in Ethiopia are likely to pay more attention to it for rehabilitating degraded areas.

The missing link an ecosystem services framework built from bamboo

According to Sisay Nune et al. (2013) the capacity to provide regulating services such as soil conservation, environmental rehabilitation and carbon sequestration of forestland and other forest types, were assumed to be 99 and 93 percent respectively as compared with bare land. Thanks to a complex network of rhizome-root systems underground.

A recent study has shown that the ecosystem services a bambooforest can provide support natural, plantations, grasslands, and farmlands. Additionally, bamboo forests have proven more effective in slope stabilization and soil erosion control compared to other land use practices such as forests and grasslands.

It has an incredible ability to restore land, making it an important contributor in reaching such global restoration agreements as the Bonn Challenge and the New York Declaration on Forests. Experts engaged in bamboo research agree that a good framework is key to improve assessment of bamboo ecosystem services and to further strengthen bamboo forests for landscape restoration globally. During this research, the experts agreed that the lack of an appropriate framework, tools and methods means that the true ecosystem services of bamboo forests have not been properly assessed.

The best ecosystem service assessment framework accounts for the significance of bamboo forests to people and policymakers. Recently, Kiran Paudyal et al. (2019) designed a framework and tested it in Nepal, Indonesia and Ethiopia.

Contributions received from local communities and government further refined it, which facilitates limited resources while offering new opportunities to connect bamboo forests with ecosystem service markets from local to global scales such as PES including payment for carbon through REDD+ programs. The recently developed framework can now be replicated in other parts of the world.

Scientists are deeply concerned that the benefits of bamboo often go unnoticed. In view of the plants important but under-appreciated benefits, Paudyal, a bamboo expert said: Bamboo recharges groundwater and it significantly absorbs carbon, but it is hardly acknowledged.

An ecosystem framework can help significantly in the promotion of bamboo forests through effective management. Case studies conducted in three countries with different contexts confirmed that bamboo forests become increasingly important, and the study also validates that bamboos benefits have been found quite common globally.

Bamboo forests in different countries and context, have proven to be the best option for both landscape restoration and the supply of various ecosystem services. These forests supply more ecosystem services than any other type of planted forests. Restoration of degraded and abandoned land with bamboo could be an effective solution to cope with poverty, hunger and climate change in many parts of the world especially in developing countries.

This research was funded by CIFOR as part of the CGIAR Research Program on Forests, Trees and Agroforestry and the International Bamboo and Rattan Organisation (INBAR), China.

(Visited 1 times, 1 visits today)

Continue reading here:

What bamboo forests do for nature and human well-being - Forests News, Center for International Forestry Research

Quorn’s secret to longevity in the meat alternative sector – Food Dive

As far as meat alternatives are concerned, there are few people who have been in the business as long as Tim Finnigan.

He's been working at U.K.-based Quorn and its preceding corporate owners since 1995, and currently works as the chief scientific adviser. Almost 25 years ago, what is now a global meat alternative giant that claims to have served nearly 5 billion meals to consumers in 17 countries, was a project at British food company Rank HovasMcDougal. It dealt with turning mycoprotein, a fermented fungus culture, into food.Finnigan, a food scientist, expected work on the project to last maybe a year or two.

"I just found it a fascination, this whole idea ... was actually rooted back in the '60sand one man's vision, which is ... very inspiring," he said. "To kind of cut a long story short, that's where I've been ever since."

Tim Finnigan

Quorn first entered the U.K. marketplace in 1985, and started being distributed there in 1993. The company's products, which include meat-free burgers, fishless sticks, sausages, deli slices, roasts and cheese cutlets, made it to North American shelves in 2002.Quorn's sales in the U.S. grew 24% in the last year, according to Ben Sussna, the brand's U.S. director of marketing and innovation practice.

Through almost a quarter century at the company and in the meat alternative space Finnigan said he has seen it all. There have been times when consumers weren't necessarily interested in the segment. And now, meat alternatives are the hottest area in food. As the category becomes crowded with upstarts and new products, Quorn, currently owned by Philippines-based noodle powerhouse Monde Nissin, isn't standing still. Finnigan said the company is investing in improving its capacity, technology and knowledge.

The idea that became the company started in the 1960s when futurists projected the human race would run out of protein by the 1990s. J. Arthur Rank, a British industrialist, instructed scientists to work toward finding a non-animal solution to this potential problem. The fungus Fusarium venenatumwas discovered in soil in 1967, and scientists figured out a process to grow, ferment and assemble it into mycoprotein, which is then dried and processed to take on the characteristics of meat.

Mycoprotein is easily adaptable to different textures and tastes, which explains why Quorn has such a wide range of products. Finnigan said part of the reason Quorn has been able to succeed is the attention the company has paid to the variety and quality of its products.

"You quickly become irrelevant if your food doesn't excite and delight the consumer or intrigue chefs. I mean, those are the two must-have things for anybody who wants to win in this space," Finnigan said. "The quality of the food has to be number one."

Quorn's long history, he said, shows the product has endurance on the market. And he hopes the food can speak for itself.

Finnigan recalled an early meeting with a U.S. company he was hoping to do a commercial partnership with about 20 years ago. The people he was presenting to didn't really seem to understand what he was talking about.

"So I stopped the presentation, said, 'Look, let's just try some of the food.' And of course, then, the lights went on and these guys said, 'Yeah, these guys are from the U.K.They've got some kicka-- products.' And the rest was really easy because they thought the food was so amazing.

Tim Finnigan

Chief science officer, Quorn

"So I stopped the presentation, said, 'Look, let's just try some of the food,' " he said. "And of course, then, the lights went on and these guys said, 'Yeah, these guys are from the U.K.They've got some kicka-- products.' And the rest was really easy because they thought the food was so amazing."

While taste is paramount to keeping Quorn on the market, so are the product's sustainability and mycoprotein's health benefits. Finnigan said Quorn promotes its sustainability and health bona fides on a regular basis. After all, the company was founded with the goal of becoming a sustainable source of food for an uncertain future. Quorn puts out annual sustainability reportsto tout its low carbon footprint and water usage. According to the company, Quorn's carbon footprint is 10 times lower than beef and four times lower than chicken. It uses 20 times less water than beef and 6 times less water than chicken.

As for its health benefits, Quorn routinely funds and participates in industry studies. The ingredient itself, the company says, has all nine amino acids, no cholesterol, high fiber and is low fat.

"We can't just separate the impact of the choices we make in our diets from the impact on the health of our bodies and the health of the planet," Finnigan said. "Those two things have to be talked about together ... and I think that that's quite an important thing,as an industry, to start discussing."

Finnigan said younger generations are more ready to discuss this and take these aspects to heart. And as long as the company can show consumers that mycoprotein is good for them and the planet, consumers will be interested. He said many companies aspire to put back more than they take out when it comes to natural resources, and Quorn is trying to show its efforts to get there.

Quorn

While several newer companies are using fermentation to create protein products including Perfect Day, which makes dairy protein that way, and Future Meat Technologies, a manufacturer of fermented meat Quorn has been at it for decades. And while the process is rather complicated, the company has been proactive in educating consumers on how the products are made.

Finnigan has starred in videos taking consumers through the process while looking right at the fermenters where the product is born. And even though the process is a bit science heavy, it also adds to transparency, something that consumers are clamoring for.

"We have to have the good quality science that actually removes consumer uncertainty," he said.

"We can't just separate the impact of the choices we make in our diets from the impact on the health of our bodies and the health of the planet. Those two things have to be talked about together ... and I think that that's quite an important thing, as an industry, to start discussing."

Tim Finnigan

Chief science officer, Quorn

Although mycoprotein is created through a lengthy process, and is heavily processed in order to become a meat substitute, Quorn's products have a cleaner label than many competitors in the meat alternative space. This is one of its biggest differentiators, Finnigan said, and one that it may not play up enough.

"We're growing our tiny little member of the fungi family, and then we're simply cooking it and freezing it to create the texture," he said. "Whereas if you want to do something like [other popular meat-free alternatives] ... you can end up with a back-of-pack label that does look a bit like a chemistry set."

Quorn also has made efforts to be transparent with its labeling. In recent years, the brand has settled lawsuitsfrom U.S. consumers who said they were misled by package statements describing mycoprotein's origin. One lawsuit, settled last year,is a wrongful death case involving a child with a mold allergy who died of anaphylactic shock after eating a Quorn product. The Center for Science in the Public Interest, which has advocated to take mycoproten off of the FDA's GRAS list, claims there have been thousands of adverse reactions to the ingredient.

While the meat alternative movement is hot, Quorn is focusing on what's next. Finnigan said the company has a three-year innovation pipeline, and is always looking for new applications for mycoprotein.

Right now, there is some work being done to try to make a drinkable version, playing into the high-protein beverage trend. The company also has been talking to U.K. restaurants about some meat-free product launches.

Finnigan said he is interested in some of the work underway in the sector, including startups such as Sustainable Bioproducts that are producing similar fermented fungal protein items. He said while each company wants profits, the meat alternative segment is more about working together toward a common goal and less about cutthroat competition. The opportunities, he said, are enormous.

"We have to find a way of assuring a sustainable food future through the creation of healthy new proteins with the low environmental impacts. Because if you look at just business as usual with small adjustments, then it doesn't look very pretty," Finnigan said. "So it is important, I think, that the new entrants come. And they bring their energy, and if it's a great food and the consumers are delighted by that, then, you know, that's got in the long term to be a good thing. It might be difficult for some organizations, you know, that are toughing it out in the marketplace, but it's so important that we win, I think, as a sector."

View post:

Quorn's secret to longevity in the meat alternative sector - Food Dive

Insurer Can’t Blame Drug Cos. For Its Inaction, 7th Circ. Told – Law360

Law360, Chicago (November 6, 2019, 2:28 PM EST) -- A Seventh Circuit judge on Wednesday pushed Medical Mutual of Ohio to address why it waited until July 2016 to take steps to limit which testosterone replacement drugs the insurer would cover, two years after the U.S. Food and Drug Administration flagged potential cardiovascular risks associated with the drugs.

During oral arguments, Medical Mutual urged the Seventh Circuit to revive its Racketeer Influenced and Corrupt Organizations Act suit against AbbVie and other makers of testosterone replacement drugs, or TRTs, saying they misrepresented those drugs as being safe and effective for a host of symptoms related to normal male aging.

But U.S....

In the legal profession, information is the key to success. You have to know whats happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

TRY LAW360 FREE FOR SEVEN DAYS

Read the original here:
Insurer Can't Blame Drug Cos. For Its Inaction, 7th Circ. Told - Law360

Incredible Growth of Testosterone Replacement Therapy Market Recent Study including Growth by 2026 – Health News Office

A Comprehensive research study conducted byKD Market Insightson Eye Testing Equipment Market- by Device {Slit Lamp, Biometer, Perimeter, Tonometer, Optical Coherence Tomography (OCT), Fundus Camera, Autorefractor and Keratometer, and Other Devices}, Application (General Examination, Glaucoma, Cataract, and Other Applications), and End User (Hospital, Eye Clinic, and Optometry Academic Institute) Global Opportunity Analysis and Industry Forecast, 2017-2025 report offers extensive and highly detailed historical, current and future market trends in the Global and regional/market. TheEye Testing Equipment Marketreport includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments.

The globaleye testing equipment marketwas valued at $2,638 million in 2017 and is expected to reach $3,914 million by 2025, registering aCAGR of 5.0%from 2018 to 2025. Ophthalmic diagnostic devices/eye testing equipment/optometry devices are used for detection and analysis of eye-related diseases such as refractive error, cataract, glaucoma, and diabetic retinopathy. These diagnostic devices are of utmost importance to provide proper treatment to the patients to avoid further damage to the vision or loss of vision.

Request for Sample @https://www.kdmarketinsights.com/sample/4184Considerable increase in the incidence of eye-associated disorders especially cataract and glaucoma across the globe has played a significant role in driving the growth of eye testing equipment market. Immediate treatment of people suffering from glaucoma is essential as glaucoma in severe cases may result in loss of vision permanently. This immediate attention is possible only when the patients undergo comprehensive eye examinations wherein eye testing devices are utilized for effective diagnosis. In addition, glaucoma is anticipated to be the leading cause of blindness among people in the age group of 60 years and above. Whereas, cataract is a condition wherein clouding of the lens occurs resulting in decreased vision, and its incidence has been on the rise over the years.

The globaleye testing equipment marketis segmented based on device, application, end user, and region. Based on device, the market is classified into slit lamp, biometer, perimeter, tonometer, optical coherence tomography (oct) scanner, fundus camera, autorefractor & keratometer, and other devices. The other devices include lensmeter, chart projector/visual acuity accessory/computerized visual acuity system, ophthalmoscope, and others. By application, it is categorized into general examination, glaucoma, cataract, and other applications. The end users covered in the study include hospital, eye clinic, and optometry academic institute. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERSThe study provides an in-depth analysis of the global eye testing equipment market with the current trends and future estimations to elucidate the imminent investment pockets.A comprehensive analysis of the factors that drive and restrict the market growth is provided.A comprehensive quantitative analysis of the industry is provided from 2017 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.An extensive analysis of the key segments of the industry helps understand the trends in eye testing equipment globally.Key players and their strategies are provided to understand the competitive outlook of the industry.

KEY MARKET SEGMENTSBy Device Slit Lamp Biometer Perimeter Tonometer Optical Coherence Tomography (OCT) Fundus Camera Autorefractor and Keratometer Other Devices

By Application General Examination Glaucoma Cataract Other Applications

By End User Hospital Eye Clinic Optometry Academic Institute

By RegionNorth America U.S. Canada MexicoEurope Germany France UK Italy Spain Rest of EuropeAsia-Pacific Japan China India Australia South Korea Rest of Asia-PacificLAMEA Brazil Saudi Arabia South Africa Rest of LAMEA

KEY MARKET PLAYERS Carl Zeiss Metall Zug AG (Haag Streit) Topcon Corporation Nidek Co., Ltd. Escalon Novartis Canon Essilor Heine Optotechnik Luneau Technology

The other players in the value chain include (profiles not included in the report) Heidelberg Engineering GmBH Huvitz BON Optic Reichert Technologies Potec Visionix Tomey Corporation LuxVision

Browse Full Report with TOC @https://www.kdmarketinsights.com/product/eye-testing-equipment-market-amrTable of Contents:

CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders1.3. Key market segments1.4. Research methodology1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW3.1. Market definition and scope3.2. Key findings3.2.1. Top investment pockets3.3. Porters five forces analysis3.4. Market share analysis, 20173.5. Market dynamics3.5.1. Drivers3.5.1.1. Rising prevalence of eye diseases across the globe3.5.1.2. Increase in the technological advancements in the field of ophthalmological diagnostics3.5.1.3. Increasing government initiatives to control visual impairment3.5.2. Restraints3.5.2.1. Dearth of skilled professionals3.5.2.2. Low accessibility to eye care in low income countries3.5.3. Opportunity3.5.3.1. Emerging nations offer profitable opportunities for eye testing equipment manufacturers

CHAPTER 4: EYE TESTING EQUIPMENT MARKET, BY DEVICE4.1. Overview4.1.1. Market size and forecast4.2. Slit Lamps4.2.1. Key trends and opportunities4.2.2. Market size and forecast4.2.3. Market analysis, by country4.3. Biometers4.3.1. Key trends and opportunities4.3.2. Market size and forecast4.3.3. Market analysis, by country4.4. Perimeters4.4.1. Key trends and opportunities4.4.2. Market size and forecast4.4.3. Market analysis, by country4.5. Tonometers4.5.1. Key trends and opportunities4.5.2. Market size and forecast4.5.3. Market analysis, by country4.6. Optical Coherence Tomography (OCT)4.6.1. Key trends and opportunities4.6.2. Market size and forecast4.6.3. Market analysis, by country4.7. Fundus Cameras4.7.1. Key trends and opportunities4.7.2. Market size and forecast4.7.3. Market analysis, by country4.8. Autorefractors and Keratometers4.8.1. Key trends and opportunities4.8.2. Market size and forecast4.8.3. Market analysis, by country4.9. Other Devices4.9.1. Key trends and opportunities4.9.2. Market size and forecast4.9.3. Market analysis, by country

CHAPTER 5: EYE TESTING EQUIPMENT MARKET, BY APPLICATIONS5.1. Overview5.1.1. Market size and forecast5.2. General Eye Examinations5.2.1. Market size and forecast5.2.2. Market analysis, by country5.3. Glaucoma5.3.1. Market size and forecast5.3.2. Market analysis, by country5.4. Cataract5.4.1. Market size and forecast5.4.2. Market analysis, by country5.5. Other Applications5.5.1. Market size and forecast5.5.2. Market analysis, by country

CHAPTER 6: EYE TESTING EQUIPMENT MARKET, BY END USER6.1. Overview6.1.1. Market size and forecast6.2. Hospitals6.2.1. Market size and forecast6.2.2. Market analysis, by country6.3. Eye Clinics6.3.1. Market size and forecast6.3.2. Market analysis, by country6.4. Optometry Academic Institutes6.4.1. Market size and forecast6.4.2. Market analysis, by country

CHAPTER 7: EYE TESTING EQUIPMENT MARKET, BY REGION7.1. Overview7.1.1. Market size and forecast7.2. North America7.2.1. Key trends and opportunities7.2.2. North America market size & forecast, by country7.2.2.1. U.S. market size & forecast, by device7.2.2.2. U.S. market size & forecast, by application7.2.2.3. U.S. market size & forecast, by end user7.2.2.4. Canada market size & forecast, by device7.2.2.5. Canada market size & forecast, by application7.2.2.6. Canada market size & forecast, by end user7.2.2.7. Mexico market size & forecast, by device7.2.2.8. Mexico market size & forecast, by application7.2.2.9. Mexico market size & forecast, by end user7.2.3. North America market size & forecast, by device7.2.4. North America market size & forecast, by application7.2.5. North America market size & forecast, by end user7.3. Europe7.3.1. Key trends and opportunities7.3.2. Europe market size & forecast for eye testing equipment market, by country7.3.2.1. Germany market size & forecast, by device7.3.2.2. Germany market size & forecast, by application7.3.2.3. Germany market size & forecast, by end user7.3.2.4. France market size & forecast, by device7.3.2.5. France market size & forecast, by application7.3.2.6. France market size & forecast, by end user7.3.2.7. UK market size & forecast, by device7.3.2.8. UK market size & forecast, by application7.3.2.9. UK market size & forecast, by end user7.3.2.10. Italy market size & forecast, by device7.3.2.11. Italy market size & forecast, by application7.3.2.12. Italy market size & forecast, by end user7.3.2.13. Spain market size & forecast, by device7.3.2.14. Spain market size & forecast, by application7.3.2.15. Spain market size & forecast, by end user7.3.2.16. Rest of Europe market size & forecast, by device7.3.2.17. Rest of Europe market size & forecast, by application7.3.2.18. Rest of Europe market size & forecast, by end user7.3.3. Europe market size & forecast, by device7.3.4. Europe market size & forecast, by application7.3.5. Europe market size & forecast, by end user7.4. Asia-Pacific7.4.1. Key trends and opportunities7.4.2. Asia-Pacific market size & forecast, by country7.4.2.1. Japan market size & forecast, by device7.4.2.2. Japan market size & forecast, by application7.4.2.3. Japan market size & forecast, by end user7.4.2.4. China market size & forecast, by device7.4.2.5. China market size & forecast, by application7.4.2.6. China market size & forecast, by end user7.4.2.7. India market size & forecast, by device7.4.2.8. India market size & forecast, by application7.4.2.9. India market size & forecast, by end user7.4.2.10. Australia market size & forecast, by device7.4.2.11. Australia market size & forecast, by applicationContinue.

Check for Discount @https://www.kdmarketinsights.com/discount/4184

About Us:

KD Market Insightsis one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends. Our in-house research experts have a wealth of knowledge in their respective domains. With KD Market Research, you always have the choice of getting customized report free of cost (up to 10%). Our support team will help you customize the report and scope as per your business needs. This ensures that you are making the right purchase decision.Our clients list includes various Fortune 500 companies and leading advisory firms.

Contact Us:KD Market Insights90 State Street, Albany,New York, USA 12207+1 (518) 300-1215Email:[emailprotected]Website:www.kdmarketinsights.comRead More News:https://foodcourt894109857.wordpress.com/https://automotiveindustry9.blogspot.com/

Read the original post:
Incredible Growth of Testosterone Replacement Therapy Market Recent Study including Growth by 2026 - Health News Office

Testosterone Replacement Therapy Market Published by Leading Research Firm – Maxi Wire

The globaltestosterone replacement therapy marketrides on the back of technology. As consumer focus shifts from access to comfort, players in the market for testosterone replacement therapy are looking at new opportunities to capitalize on the potential. This exclusive report from Transparency Market Research will take you through an extensive analysis of every aspect in the testosterone replacement therapy market that is critical for defining your success strategy. It offers prudent information on markets under currents, trends that will open new doors, factors that will remain important, challenges that need to be overcome, prevailing competition in the market, and the geographical landscape.

Based on a tested and proven research methodology, our research analysts bring to you fact-checked information. Besides presenting the current market figures, our analysts provide you with accurate forecasts that can be the game-changer for your winning strategies for tomorrow. On the other hand, our reports also offer tailor-made insights. Further, our reports are packed with experts viewpoints which are transcribed from interviews conducted by our analysts.

For Right Perspective & Competitive Insights,Request For A Sample Here

For every market, information on leading players can be the difference between success and failure, be it a prominent brand or not. Our reports cover every significant players in the global testosterone replacement therapy market providing information about the company profile, products, winning strategies and market revenues. Not just that, TMR also provides information on the competitive landscape, helping you understand what impacted in one company being the market leader and others not. It also explains on the companies imperatives that define their success in the global market for testosterone replacement therapy.

Healthcare, unlike most industries, is typical of the region. Humans have multiple races and hence their genetic makeups are different. As a result, one condition has different impacts depending on the region. Therefore, information on how consumer requirements are different in regional landscape of the global testosterone replacement therapy is provided her in the report. Further, the economic capabilities of a country has a huge impact on healthcare infrastructure. TMRs report analysis the current economic scenario and also brings to you information on affordability during the coming years.

To Clarify Your Doubts About The Report,Request A Brochure Here

From market share to region-specific strategies, the report covers it all. At the same time, players in the testosterone replacement therapy market who are looking to expand might want to assess the potential of a prospective region. Our reports can provide you with custom-made insights for specific regions in the global testosterone replacement therapy market. The geographical analysis also covers regions-specific factors that could turn out to be hurdle for growth in the coming years.

Original post:
Testosterone Replacement Therapy Market Published by Leading Research Firm - Maxi Wire

Testosterone Replacement Therapy Market Top key Players, Size, Share, Demand, Opportunities And Forecasts To 2025 – Weekly Spy

Testosterone Replacement Therapy Market primary data collection was achieved by interviewing the retailers and the consumers. The interviews were conducted through one to one structured questionnaire supervision.

Global Testosterone Replacement Therapy Market report provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast timespan.

In order to present an executive-level model of the market and its future perspectives, Testosterone Replacement Therapy Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Request Exclusive Free Sample PDF Of This Report At https://dataintelo.com/request-sample/?reportId=110389

Major Players included in this report are as follows

AbbVie Endo International Eli lilly Pfizer Actavis (Allergan) Bayer Novartis Teva Mylan Upsher-Smith Ferring Pharmaceuticals Kyowa Kirin Acerus Pharmaceuticals

Testosterone Replacement Therapy Market can be segmented into Product Types as

Gels Injections Patches Other

Testosterone Replacement Therapy Market can be segmented into Applications as

Hospitals Clinics Others

Testosterone Replacement Therapy Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

The research provides answers to the following key questions: What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Testosterone Replacement Therapy? Who are the global key manufacturers of Testosterone Replacement Therapy industry? How are their operating situation (capacity, production, price, cost, gross and revenue)? What are the types and applications of Testosterone Replacement Therapy? What is the market share of each type and application? What are the upstream raw materials and manufacturing equipment of Testosterone Replacement Therapy? What is the manufacturing process of Testosterone Replacement Therapy? Economic impact on Testosterone Replacement Therapy industry and development trend of Testosterone Replacement Therapy industry. What will the Testosterone Replacement Therapy market size and the growth rate be in 2025? What are the key factors driving the global Testosterone Replacement Therapy industry? What are the key market trends impacting the growth of the Testosterone Replacement Therapy market? What is the Testosterone Replacement Therapy market challenges to market growth? What are the Testosterone Replacement Therapy market opportunities and threats faced by the vendors in the global Testosterone Replacement Therapy market?

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=110389

Testosterone Replacement Therapy Market track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, research and developments, with respect to the current market size and future prospective.

For Best Discount on purchasing this report, Visit https://dataintelo.com/ask-for-discount/?reportId=110389

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Read More Trending News at Top Special Reports

Contact Info Name Alex MathewsPhone +1 909 545 6473Email sales@dataintelo.comWebsite https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

Continue reading here:
Testosterone Replacement Therapy Market Top key Players, Size, Share, Demand, Opportunities And Forecasts To 2025 - Weekly Spy

Go or no go? Agile and Lipocine hope to make it third time lucky – Vantage

After some huge US approvals in recent months, November is shaping up to be quieter. There are no decisions on future blockbusters set for next month, Vantages regular PDUFA analysis shows.

However, some of the upcoming verdicts will still be a big deal for the companies involved. This includes Agile Therapeutics and Lipocine, which hope to bounce back from complete response letters for the Twirla contraceptive patch and the testosterone replacement therapy Tlando respectively.

Twirla's chances of getting approved got a boost yesterday, with an FDA advisory committee voting 14-1 that the benefits of the projects outweigh its risks an unexpected outcome given scathing briefing documentsreleased on Monday. The agency questioned the patch's efficacy, thoughAgile put unimpressive results from the pivotal Secure trial down to a high number of obese participants, in whom contraceptives do not work as well.

The FDA questioned Twirla's efficacy even in non-obese women, however, and also raised doubts about whether the project is a low-dose, and therefore potentially safercontraceptive, as Agile has claimed. Shares in the company recovered today after slumping on the briefing docs, but investors' wild ride might not be over yet.

Meanwhile, Lipocine will hope that an ambulatory blood pressure study will answer questions raised in the FDAs May 2018 CRL. The company believes that Tlando, an oral therapy, will have an edge over injectable testosterone products. Another oral contender got the FDA nod earlier this year, Clarus Therapeutics Jatenzo, andLipocine is embroiled in a legal wrangle with Clarus over intellectual property.

A project that should get a smoother ride is Shionogis S-649266, or cefiderocol, a novel antibiotic targeting Gram-negative pathogens. The project recently got an adcom thumbs up, with panellists voting14-2 in favour ofapproval for patients with complicated urinary tract infections and limited or no alternative treatment options.

The project has also shown promise in pneumonia. Still, as with many antibiotics, especially those saved for drug-resistant infections, succeeding commercially will be trickier.

Meanwhile, Redhill Biopharmas Talicia, which combines two antibiotics and a proton pump inhibitor, is awaiting a verdict in Helicobacter pylori infection. It has a good shot after a positive result in the Eradicate Hp2 trial, and a recent tie-up with Cosmo Pharmaceuticals should also give Redhill sufficient funds for launch.

However, sales expectations are not huge, with EvaluatePharma consensus predicting $27m in 2024.

Supplements

As for potential supplementary approvals, Lilly and Boehringer hope to get cardiovascular data on the label of their DPPIV inhibitor Tradjenta. However, the product has only shown noninferiority to placebo in the Carmelina study; with other diabetes drugs like the SGLT2s and GLP1s showing cardioprotective effects, the DPPIV class has been put in the shade.

Other decisions, including a verdict on Pfizers Humira biosimilar, continue to be expected sometime in the fourth quarter.

The biggest regulatory event of November is not an approval but rather an advisory committee meeting, for Amarins Vascepa. On November 14 panellists will consider the products expanded use for the reduction of cardiovascular events in patients with high triglycerides; the FDA had previously been expected to make a call here in September.

EvaluatePharma consensus forecasts 2024 Vascepa sales of $2.2bn, but Leerink analysts believe that, if the drug does get expanded approval, US revenues could exceed $4bn.

Original post:
Go or no go? Agile and Lipocine hope to make it third time lucky - Vantage

Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 – Zebvo

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally. Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period. Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Nature of global male hypogonadism market has been observed to be highly competitive. This can be mainly attributed to occupancy of many small as well as large suppliers. New companies entering the male hypogonadism market are leveraging opportunities related to treatment developments and innovations. Strategic alliances are likely to remain strong among vendors for producing and marketing drugs worldwide, thereby increasing their market reach. Active market players listed by PMRs report include Astrazeneca Plc., Merck & Co. Inc., Laboratories Genevrier, Bayer AG, Endo International Plc., Allergan Plc., Ferring, Finox Biotech, AbbVie Inc., Eli Lilly and Company Ltd., Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimque.

Go here to read the rest:
Male Hypogonadism Market Expand at the Fastest CAGR of 3.7% Throughout the Forecast Quantity 2017-2026 - Zebvo

Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies -…

The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new Reserach Report

Testosterone Replacement Therapy Market2019 Research report contains a qualified and in-depth examination of Testosterone Replacement Therapy Market. At first, the report provides the current Testosterone Replacement Therapy business situation along with a valid assessment of the Testosterone Replacement Therapy business. Testosterone Replacement Therapy report is partitioned based on driving Testosterone Replacement Therapy players, application and regions. The progressing Testosterone Replacement Therapy economic situations are additionally discovered in the report.

Short Description About Testosterone Replacement Therapy Market :

Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development.

Get Sample PDF of reporthttps://www.360researchreports.com/enquiry/request-sample/13836798

The research covers the current market size of the Testosterone Replacement Therapy market and its growth rates based on 5-year records with company outline ofKey players/manufacturers:

Scope Of The Report :

Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%. Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry. The worldwide market for Testosterone Replacement Therapy is expected to grow at a CAGR of roughly -4.2% over the next five years, will reach 1410 million US$ in 2024, from 1820 million US$ in 2019, according to a new research study.This report focuses on the Testosterone Replacement Therapy in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/13836798

Report further studies the Testosterone Replacement Therapy market development status and future trend across the world. Also, it splits Testosterone Replacement Therapy market by Type and by Applications to fully and deeply research and reveal market profile and prospects.

Major Classifications are as follows:

Major Applications are as follows:

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Testosterone Replacement Therapy in these regions, from 2014 to 2024, covering

The Testosterone Replacement Therapy market report provides answers to the following key questions:

Purchase this report (Price 3480 USD for a single-user license) https://www.360researchreports.com/purchase/13836798

Major Points from Table of Contents:

1 Market Overview1.1 Testosterone Replacement Therapy Introduction1.2 Market Analysis by Type1.3 Market Analysis by Applications1.4 Market Dynamics1.4.1 Market Opportunities1.4.2 Market Risk1.4.3 Market Driving Force

2.Manufacturers Profiles

2.4.1 Business Overview2.4.2 Testosterone Replacement Therapy Type and Applications2.4.2.1 Product A2.4.2.2 Product B

3.Global Testosterone Replacement Therapy Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

3.1 Global Testosterone Replacement Therapy Sales and Market Share by Manufacturer (2017-2018)3.2 Global Testosterone Replacement Therapy Revenue and Market Share by Manufacturer (2017-2018)3.3 Market Concentration Rate3.3.1 Top 3 Testosterone Replacement Therapy Manufacturer Market Share in 20183.3.2 Top 6 Testosterone Replacement Therapy Manufacturer Market Share in 20183.4 Market Competition Trend

4 Global Testosterone Replacement Therapy Market Analysis by Regions

4.1 Global Testosterone Replacement Therapy Sales, Revenue and Market Share by Regions4.1.1 Global Testosterone Replacement Therapy Sales and Market Share by Regions (2014-2019)4.1.2 Global Testosterone Replacement Therapy Revenue and Market Share by Regions (2014-2019)4.2 North America Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.3 Europe Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.4 Asia-Pacific Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.6 South America Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)4.6 Middle East and Africa Testosterone Replacement Therapy Sales and Growth Rate (2014-2019)

6 Testosterone Replacement Therapy Market Forecast (2019-2024)6.1 Global Testosterone Replacement Therapy Sales, Revenue and Growth Rate (2019-2024)6.2 Testosterone Replacement Therapy Market Forecast by Regions (2019-2024)6.3 Testosterone Replacement Therapy Market Forecast by Type (2019-2024)6.3.1 Global Testosterone Replacement Therapy Sales Forecast by Type (2019-2024)6.3.2 Global Testosterone Replacement Therapy Market Share Forecast by Type (2019-2024)6.4 Testosterone Replacement Therapy Market Forecast by Application (2019-2024)6.4.1 Global Testosterone Replacement Therapy Sales Forecast by Application (2019-2024)6.4.2 Global Testosterone Replacement Therapy Market Share Forecast by Application (2019-2024)

6.Sales Channel, Distributors, Traders and Dealers6.1 Sales Channel6.1.1 Direct Marketing6.1.2 Indirect Marketing6.1.3 Marketing Channel Future Trend6.2 Distributors, Traders and Dealers

7. Research Findings and Conclusion

8. Appendix8.1 Methodology8.2 Data Source

Continued..

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:Name: Mr. Ajay MoreEmail: [emailprotected]Organization: 360 Research ReportsPhone: +44 20 3239 8187/ +14242530807

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies

See the article here:
Testosterone Replacement Therapy Market 2019 to 2024 With Top Countries Data : Opportunities, Industry Trends and Policies by Regions and Companies -...

Testosterone Replacement Therapy Market Outlook: Heading To the Clouds – Daily Market Insight

Europe Testosterone Replacement Therapy study will help you investigate a detailed division of the market by the end user/industry, by best in class product type and by geography with creation, income, utilization, export & import data in these areas, crunching historical data along with primaries and opinion leaders and industry experts interview and estimate with detailed driving factors for forcasted period.

Get Sample Report PDF With More Details And Graph @https://www.htfmarketreport.com/sample-report/1631438-europe-testosterone-replacement-therapy-market-1The Europe Testosterone Replacement Therapy is relied upon to come to an expected $XX.X billion by 2025 and it is a gauge to develop at a CAGR of X.X% for forecast period. This report centers around top makers in the Europe Testosterone Replacement Therapy, with generation, value, income, and market share for every producer/manufacturers.

Top Testosterone Replacement Therapy Manufacturers:AbbVie, Allergan, Eli Lilly, Endo International, Acerus Pharmaceutical Corporation, Antares Pharma, Bayer HealthCare Pharmaceuticals, Bedford Labs, Clarus Therapeutics, Ferring Pharmaceuticals, Forendo Pharma, Juniper Pharmaceuticals, Lipocine, MetP Pharma, Mylan, Pfizer, ProStrakan, Repros Therapeutics, Sandoz, TesoRx & Teva Pharmaceuticals.Testosterone Replacement Therapy Report Focusing By Types:, Gels, Injectables & Patches

Testosterone Replacement Therapy Report Focusing By Applications:Hospitals & Clinics

Testosterone Replacement Therapy Report Focusing By Regions:Germany, France, UK, Russia, Italy, Spain & Benelux

For Detail View Of TOC (Table Of Content) @https://www.htfmarketreport.com/reports/1631438-europe-testosterone-replacement-therapy-market-1Testosterone Replacement Therapy Report shows a detailed overview of the market by strategy for study, mix, and data evaluated from different sources. The pros have presented the various appearances of the market with a particular, base on recognizing Testosterone Replacement Therapy business influencers.

Have Any Query? Ask Our Expert @https://www.htfmarketreport.com/enquiry-before-buy/1631438-europe-testosterone-replacement-therapy-market-1This Report Will Give a Nitty-Gritty Evaluation of Significantly Accompanying:

Item outline and extent of Europe Testosterone Replacement TherapySignificant players in the Europe Testosterone Replacement Therapy Market.Europe Testosterone Replacement Therapy players/providers Profiles and Sales information.Testosterone Replacement Therapy Marketing procedure examination and improvement patterns.Testosterone Replacement Therapy Market impact factor examination.Developing specialty fragments and local Testosterone Replacement Therapy markets.An experimental evaluation of the direction of the Testosterone Replacement Therapy.Real changes in Testosterone Replacement Therapy elements/ sub industry segments.Chronicled, present, and imminent size of the Testosterone Replacement Therapy from the point of view of both revenue and sales volume and average price.

It is vital for an organization to have the capacity to catch the mindshare of their gathering of people as it is characteristic for an organization which is planning to see a development in the Europe Testosterone Replacement Therapy. This is conceivable through a knowledgeable network administration and develops an advertising plan for the Europe Testosterone Replacement TherapyIndustry.

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=1631438Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter

Original post:
Testosterone Replacement Therapy Market Outlook: Heading To the Clouds - Daily Market Insight

After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings Expectations (NYSE:ABBV) – Stock Investor

After its stock gained a third of its value over the past 60 days, AbbVie, Inc. (NYSE:ABBV) beat revenue and earnings expectations and obtained potential fuel that may allow it to extend its current share price uptrend.

The companys share price exhibited steady growth and more than doubled from its initial public opening (IPO) price of $34.40 to more than $75 by August 2017. After a brief spike to nearly $125 over the next five months, the share price reversed direction and gave back those quick gains by the beginning of 2019.

However, the chart below illustrates that the share price was still at its long-term uptrend in January 2019. However, after dropping further, the share price has been rising steadily since mid-August 2019 and the positive results from the current quarterly report should continue to power the current share price recovery.

Released on November 1, AbbVies report for the third quarter of 2019 which ended on September 30, 2019 revealed a 3% increase in worldwide net revenues to $8.48 billion. Diluted earnings per share (EPS) were $1.26. The adjusted EPS of $2.33 was nearly 9% above the $2.14 adjusted EPS from the same period last year and beat analysts earnings expectations of $2.29 by 1.75%. After missing earnings estimates by 2% in the last quarter of 2018, AbbVie managed to beat earnings expectations in the last three consecutive quarters and four times in the last five periods.

The companys current $1.07 quarterly dividend is 11.5% higher than the companys $0.96 payout from the same quarter last year. This new quarterly payout corresponds to a $4.28 annualized distribution. Using the $79.55 share price as of closing on October 31, 2019, the current payout is equivalent to a 5.38% forward dividend yield. This is 32.5% above the companys own 4.06% yield average over the past five years.

Additionally, AbbVies current yield level is the highest among the companys peers in the Major Drug Manufacturers market segment. Furthermore, AbbVies current yield is at least 20% higher than the segments only other yields in excess of 4% Takeda Pharmaceutical Co Ltd (NYSE:TAK) at 4.51% and GlaxoSmithKline Plc (NYSE:GSK) at 4.37%. As the segments top value, AbbVies current yield is nearly triple the segments 1.8% simple average, as well as nearly double the 2.8% average yield of the segments only dividend paying companies. Furthermore, in a sector that is renowned for its low dividend payouts, AbbVies current yield is nearly 10-fold higher than the 0.52% simple yield average of the entire Health Care sector.

As a separate legal entity, AbbVies current streak of consecutive annual dividend hikes only goes back six years. However, the companys history of dividend payouts as part of Abbot Labs goes back several decades. In 2013 the year of the divestiture from Abbott Laboratories the two companies paid individual dividends. However, the sum of the two payouts was higher than Abbott Laboratories total dividend payout over the previous year. Furthermore, both companies have continued to hike their respective annual dividends every year since 2013.

Therefore, we can give credit for the past dividend hikes to both companies and consider the annual dividend hikes since 2012 to be a continuation of the previous streak. Under that assumption, AbbVie has boosted its annual dividend payout for the past 46 consecutive years. Since AbbVie is a component of the S&P 500 Index and meets all the other market capitalization, liquidity and trading volume requirements, we can include the company as a part of the S&P 500 Dividend Aristocrats group.

Even disregarding the dividend distributions that were delivered prior to 2013, AbbVie has enhanced its annual dividend distribution amount by nearly 170% just over the past six years that it has been its own business entity. That level of advancement corresponds to an average growth rate of nearly 18% per year.

The share price entered the trailing 12-month period by riding the downtrend that began in January 2018. After passing through its 52-week low of $94.27 on November 30, 2018, the share price declined by nearly 50% before reaching the 52-week low of $62.98 on August 15, 2019.

However, since reversing its trend in mid-August, the share price has recovered more than half of its losses since the November peak and closed on October 31, 2019, at $79.55. This was flat with the price level of one year ago and 26% higher than the 52-week low from August. Furthermore, the share price surged 3.5% on positive financial results in just the first hour of trading on Nov. 1. The share price trailed off a little afterwards even though it held on to a 2.5% gain as of noon on the same day.

With the share price at last years levels, dividend income payouts have contributed all of the total gains of approximately 5% over the trailing 12 months. However, capital gains have contributed most of the total gains of more than 60% over the past three years.

Headquartered in North Chicago, Illinois, and founded when Abbott Labs (NYSE:ABT) divested its proprietary pharmaceutical business in 2013, AbbVie Inc. discovers, develops, manufactures and sells pharmaceutical products. The most prominent pharmaceutical brands in the companys current portfolio are HUMIRA for the treatment of autoimmune diseases, IMBRUVICA for the treatment of patients with chronic lymphocytic leukemia and VIEKIRA PAK for the treatment of adults with hepatitis C. Additionally, AbbVie offers pharmaceutical treatments for HIV, hypothyroidism, prostate cancer, endometriosis, anemia, Parkinsons disease and multiple sclerosis, as well as treatments for testosterone replacement therapy and pancreatic enzyme therapy for exocrine pancreatic insufficiency.

Ned Piplovicis the assistant editor of website content at Eagle Financial Publications. He graduated from Columbia University with a Bachelors degree in Economics and Philosophy. Prior to joining Eagle, Ned spent 15 years in corporate operations and financial management. Ned writes forwww.DividendInvestor.comandwww.StockInvestor.com.

See the rest here:
After Gaining 33% in 60 Days, AbbVie Beats Third-Quarter Earnings Expectations (NYSE:ABBV) - Stock Investor

IBM vs. Google and the Race to Quantum Supremacy – Citizen Truth

Though IBM contests Googles claim of quantum supremacy, it concedes that it passed an important milestone. For the science of computing, that is all that matters.

Googles quantum supremacy claim has now been disputed by its close competitor IBM. Not because Googles Sycamore quantum computers calculations are wrong, but because Google had underestimated what IBMs Summit, the most powerful supercomputer in the world, could do. Meanwhile, Googles paper, which had accidentally been leaked by a NASA researcher, has now been published in the prestigious science journal Nature. Googles claims are official now, and therefore can be examined in the way any new science claim should be examined: skeptically until all the doubts are addressed.

Previously, I have covered what quantum computing is, and in this article, I will move on to the key issue of quantum supremacy, the claim that IBM has challenged and what it really means. IBM concedes that Google has achieved an important milestone, but does not accept that it has achieved quantum supremacy.

IBM refuted Googles claim around the same time as Googles Nature paper was published. Google had claimed that IBMs supercomputer, Summit, would take 10,000 years to solve the problem Googles Sycamore had solved in a mere 200 seconds. IBM showed that Summit, with clever programming and using its huge disk space, could actually solve the problem in only 2.5 days. Sycamore still beat Summit on this specific problem by solving it 1,100 times faster, but not 157 million times faster, as Google had claimed. According to IBM, this does not establish quantum supremacy as that requires solving a problem a conventional computer cannot solve in a reasonable amount of time. Two and a half days is reasonable, thereforeaccording to IBMquantum supremacy is yet to be attained.

The original definition of quantum supremacy was given by John Preskill, on which he now has second thoughts. Recently he wrote, supremacy, through its association with white supremacy, evokes a repugnant political stance. The other reason is that the word exacerbates the already overhyped reporting on the status of quantum technology.

Regarding IBMs claim that quantum supremacy has not yet been achieved, Scott Aaronson, a leading quantum computing scientist, wrote that though Google should have foreseen what IBM has done, it does not invalidate Googles claim. The key issue is not that Summit had a special way to solve the specific quantum problem Google had chosen, but that Summit cannot scale: if Googles Sycamore goes from 53 to 60 qubits, IBM will require 33 Summits; if to 70 Qubits, a supercomputer the size of a city!

Why does Summit have to increase at this rate to match Sycamores extra qubits? To demonstrate quantum supremacy, Google chose the simulation of quantum circuits, which is similar to generating a sequence of truly random numbers. Classical computers can produce numbers that appear to be random, but it is a matter of time before they will repeat the sequence.

The resourcesdisk space, memory, computing powerclassical computers require to solve this problem, in a reasonable time, increase exponentially with the size of the problem. For quantum computers, adding qubits linearlymeaning, simply adding more qubitsincreases computing capacity exponentially. Therefore, just 7 extra qubits of Sycamore means IBM needs to increase the size of Summit 33 times. A 17-qubit increase of Sycamore needs Summit to increase by thousands of times. This is the key difference between Summit and Sycamore. For each extra qubit, a conventional computer will have to scale its resources exponentially, and this is a losing game for the conventional computer.

We have to give Google the victory here, not because IBM is wrong, but because the principle of quantum supremacy, that a quantum computer can work as designed, solve a specific problem, and beat a conventional computer in computational time has been established. The actual demonstrationa more precise definition of reasonable time and its physical demonstrationis only of academic value. If 53 qubits can solve the problem, but with IBMs Summit still in the race, even if much slower, it is just a matter of time before it is well and truly beaten.

Of course, there are other ways that this particular test could fail. A new algorithm can be discovered that solves this problem faster, starting a fresh race. But the principle here is not a specific race but the way quantum computing will scale in solving a certain class of problems that classical or conventional computers cannot.

For problems that do not increase exponentially with size, the classical computers work better, are way cheaper, and do not require near absolute zero temperatures that quantum computers require. In other words, classical computers will coexist with quantum computers and not follow typewriters and calculators to the technology graveyards.

The key issue in creating viable quantum computers should not be confused with a race between classical computers and the new kid on the block. If we see the race as between two classes of computers only in terms of solving a specific problem, we are missing the big picture. It is simply that for classical computers, the solution time for a certain class of problems increases exponentially with the size of the problem, and beyond a certain size, we just cant solve them in any reasonable time. Quantum computers have the potential to solve such large problems requiring exponential computing power. This opens a way to solve these classes of problems other than the iffy route of finding new algorithms.

Are there such problems, and will they yield worthwhile technological applications? The Google problem, computing the future states of quantum circuits, was not chosen for any practical application. It was simply chosen to showcase quantum supremacy, defined as a quantum computer solving a problem that a classical computer cannot solve in a reasonable time.

Recently, a Chinese team led by Pan Jianwei has published a paper that shows another problema Boson sampling experiment with 20 photonscan also be a pathway to show quantum supremacy. Both these problems are constructed not to showcase real-world applications, but simply to show that quantum computing works and can potentially solve real-world problems.

What are the classes of problems that quantum computers can solve? The first are those for which the late Nobel laureate Richard Feynman had postulated quantum computers as a simulation of the quantum world. Why do we need such simulations, after all, we live in the macro-world in which quantum effects are not visible? Though such effects may not visible to us, they are indeed all around us and affect us in different ways.

A number of such phenomena arise out of the interaction of the quantum world with the macro-world. It is now clear that using classical computers we cannot simulate, for instance, protein folding, as it involves the quantum world intersecting with the macro-world. A quantum computer could simulate the probability of how many possible ways such proteins could fold and the likely shapes they could take. This would allow us to build not only new materials but also medicines known as biologics. Biologics are large molecules used for treating cancer and auto-immune diseases. They work due to not only their composition but also their shapes. If we could work out their shapes, we could identify new proteinsor new biological drug targets; or complex new chemicals for developing new materials. The other examples are solving real-life combinatorial problems such as searching large databases, cracking cryptographic problems, improved medical imaging, etc.

The business worldIBM, Google, Microsoftis gung-ho on the possible use of quantum computers for such applications, and that is why they are all investing in it big time. Nature reported that in 2017 and 2018, at least $450 million was invested by venture capital in quantum computing, more than four times more than the preceding two years. Nation-states, notably the United States and China, are also investing billions of dollars each year.

But what if quantum computers do not lead to commercial benefitsshould we then abandon them? What if they are useful only for simulating quantum mechanics and understanding that world better? Did we build the Hadron Colliderinvesting $13.25 billion, and with an annual running cost of $1 billiononly because we expected discoveries that will have commercial value? Or, should society invest in knowing the fundamental properties of space and time including that of the quantum world? Even if quantum computers only give us a window to the quantum world, the benefits would be knowledge.

What is the price of this knowledge?

This article was produced in partnership by Newsclick and Globetrotter, a project of the Independent Media Institute.

Read more here:

IBM vs. Google and the Race to Quantum Supremacy - Citizen Truth

Microprotein ID’d Affecting Protein Folding and Cell Stress Linked to Diseases Like Huntington’s, Study Finds – Huntington’s Disease News

PIGBOS a newly discovered mitochondrial microprotein involved in a cellular stress-response mechanism called unfolded protein response (UPR) might be a treatment target for neurodegenerative diseases likeHuntingtons, a study suggests.

The study, Regulation of the ER stress response by a mitochondrial microprotein, was published in the journal Nature Communications.

Maintenance of protein balance including the production, shaping (folding), and degradation of proteins is essential for a cells function and survival.

Dysfunction in protein balance has been associated with the build-up of toxic protein aggregates and the development of neurodegenerative diseases, including Alzheimers, Parkinsons, and Huntingtons disease.

The endoplasmic reticulum (ER) is a key cellular structure in the production, folding, modification, and transport of proteins. Excessive amounts of unfolded or misfolded proteins (proteins with abnormal 3D structures) in the ER results in ER stress, and the activation of the unfolded protein response (UPR) stress response mechanism, which acts to mitigate damage caused by this protein build-up.

UPR promotes the reduction of protein production and an increase in protein folding and degradation of unfolded proteins in the ER. If this fails to restore cellular balance and prolongs the activation of UPR, cell death is induced.

UPR dysfunction contributes to accumulation of key disease-related proteins, and thus plays an essential role in the [development] of many neurodegenerative disorders, including Alzheimers disease, Parkinsons disease, and Huntingtons disease, the researchers wrote.

During UPR, mitochondria the cells powerhouses are known to provide energy for protein folding in the ER and to activate cell death pathways if the cellular balance is not restored. However, how mitochondria and the ER communicate in this context remains unclear.

Researchers at the Salk Institute for Biological Studies, in California, discovered a mitochondrial microprotein, called PIGBOS, that regulates UPR at the sites of contact between mitochondria and the ER.

While the average human protein contains around 300 amino acids (the building blocks of proteins), microproteins have less than 100 amino acids. Microproteins were only recently found to be functional and important in the regulation of several cellular processes.

By conducting protein-binding experiments, the team found that the 54-aminoacidmicroprotein PIGBOS, present in the outer membrane of mitochondria, interacts with a protein called CLCC1 at the ER-mitochondria contact sites.

CLCC1 whose low levels werepreviously associated with increased UPR and neurodegeneration is found at the portion of the ER that contacts the mitochondria, called mitochondria-associated ER membrane.

Further analyses showed that inducing ER stress in cells genetically modified to lack CLCC1 or PIGBOS increased the levels of UPR-related proteins, while the opposite effect was observed in cells overproducing PIGBOS. Lower levels of PIGBOS were also associated with greater cell death.

Researchers noted that these findings suggest that loss of PIGBOS increases cellular sensitivity to ER stress, which in turn increases [cell death] and links PIGBOS levels to the ability of cells to survive stress, emphasizing that modulating PIGBOS levels can in turn modulate cellular sensitivity towards ER stress.

Results also showed that PIGBOSs UPR regulation is dependent on its interaction with CLCC1, and that modulating the number of ER-mitochondria contacts regulates the levels of PIGBOS-CLCC1 interactions.

These data identified PIGBOS as a [previously] unknown mitochondrial regulator of UPR, and the only known microprotein linked to the regulation of cell stress or inter-organelle signaling, the team emphasized.

These findings may help in developing treatment approaches targeting ER stress and cell death.

Given the importance of UPR in biology and disease, future studies on PIGBOSs role in UPR should afford additional insights and may provide methods for regulating this pathway for therapeutic applications, the researchers concluded.

Total Posts: 79

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Excerpt from:

Microprotein ID'd Affecting Protein Folding and Cell Stress Linked to Diseases Like Huntington's, Study Finds - Huntington's Disease News